Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Aurora A kinase inhibitor MLN8237 and bortezomib may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I/II trial is studying the side effects and best dose of giving aurora A
kinase inhibitor MLN8237 together with bortezomib and to see how well they work in treating
patients with relapsed or refractory multiple myeloma.